{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:33:11Z","timestamp":1793507591889,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Health Development Fund","award":["201614035"],"award-info":[{"award-number":["201614035"]}]},{"name":"CAMS Major Collaborative Innovation Project","award":["2016-I2M-1-011"],"award-info":[{"award-number":["2016-I2M-1-011"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2019-XHQN09"],"award-info":[{"award-number":["2019-XHQN09"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Research Fund of Peking Union Medical College","award":["2019-F11"],"award-info":[{"award-number":["2019-F11"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chinese Cardiovascular Association-V.G Fund","award":["2017-CCA-VG-017"],"award-info":[{"award-number":["2017-CCA-VG-017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with coronary artery disease (CAD) with different glucose status has not been established. This study sought to evaluate the significance of NT-proBNP in predicting major adverse cardiovascular events (MACEs) in patients with chronic coronary syndrome (CCS) and normal left-ventricular systolic function (LVSF) according to different glucose status, especially in those with abnormal glucose metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 8062 patients with CCS and normal LVSF were consecutively enrolled in this prospective study. Baseline plasma NT-proBNP levels were measured. The follow-up data of all patients were collected. Kaplan-Meier and Cox regression analyses were used to assess the risk of MACEs according to NT-proBNP tertiles stratified by glucose status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over an average follow-up of 59.13\u2009\u00b1\u200918.23 months, 569 patients (7.1\u2009%) suffered from MACEs, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Kaplan-Meier analysis showed that high NT-proBNP levels had a significant association with MACEs in subjects with prediabetes mellitus (pre-DM) or DM, but not in patients with normoglycemia. Multivariate Cox regression analysis revealed that NT-proBNP remained an independent predictor of MACEs in patients with pre-DM [hazard ratio (HR): 2.56, 95% confidence interval (CI): 1.34\u20134.91] or DM (HR: 2.34, 95% CI: 1.32\u20134.16). Moreover, adding NT-proBNP to the original Cox model including traditional risk factors significantly increased the C-statistic by 0.035 in pre-DM and DM, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study indicated that NT-proBNP could well predict worse outcomes in dysglycemic patients with CCS and normal LVSF, suggesting that NT-proBNP may help with risk stratification in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-021-01271-0","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T11:04:54Z","timestamp":1619089494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Hui-Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Xuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Lu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-4364","authenticated-orcid":false,"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"41","key":"1271_CR1","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1093\/eurheartj\/ehz394","volume":"40","author":"C Zhang","year":"2019","unstructured":"Zhang C, Jiang L, Xu L, Tian J, Liu J, Zhao X, et al. Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. Eur Heart J. 2019;40(41):3397\u2013405.","journal-title":"Eur Heart J"},{"issue":"5","key":"1271_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1177\/1741826711420015","volume":"19","author":"M Clodi","year":"2012","unstructured":"Clodi M, Resl M, Neuhold S, Hulsmann M, Vila G, Elhenicky M, et al. A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol. 2012;19(5):944\u201351.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"1271_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ejheart.2003.12.012","volume":"6","author":"R Pfister","year":"2004","unstructured":"Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail. 2004;6(3):289\u201393.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"1271_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ejhf.1359","volume":"21","author":"R Rorth","year":"2019","unstructured":"Rorth R, Jhund PS, Kristensen SL, Desai AS, Kober L, Rouleau JL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019;21(1):40\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"1271_CR5","first-page":"1182","volume":"105","author":"K Salah","year":"2019","unstructured":"Salah K, Stienen S, Pinto YM, Eurlings LW, Metra M, Bayes-Genis A, et al. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart. 2019;105(15):1182\u20139.","journal-title":"Heart"},{"issue":"15","key":"1271_CR6","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","volume":"110","author":"P Bettencourt","year":"2004","unstructured":"Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168\u201374.","journal-title":"Circulation"},{"issue":"1","key":"1271_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12933-020-01080-x","volume":"19","author":"B von Jeinsen","year":"2020","unstructured":"von Jeinsen B, Ritzen L, Vietheer J, Unbehaun C, Weferling M, Liebetrau C, et al. The adipokine fatty-acid binding protein 4 and cardiac remodeling. Cardiovasc Diabetol. 2020;19(1):117.","journal-title":"Cardiovasc Diabetol"},{"key":"1271_CR8","doi-asserted-by":"publisher","first-page":"170420","DOI":"10.1016\/j.peptides.2020.170420","volume":"135","author":"MSS Knudsen","year":"2021","unstructured":"Knudsen MSS, Eismark F, Goetze JP, Gustafsson F, Wolsk E. The contribution of cardiac and extracardiac factors to NT-proBNP concentrations in patients with advanced heart failure before and after left ventricular assist device implantation. Peptides. 2021;135:170420.","journal-title":"Peptides"},{"issue":"9","key":"1271_CR9","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1177\/2047487313490256","volume":"21","author":"K Kara","year":"2014","unstructured":"Kara K, Mahabadi AA, Berg MH, Lehmann N, Mohlenkamp S, Kalsch H, et al. Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study. Eur J Prev Cardiol. 2014;21(9):1171\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1271_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00392-013-0628-4","volume":"103","author":"K Kara","year":"2014","unstructured":"Kara K, Mahabadi AA, Geisel MH, Lehmann N, Kalsch H, Bauer M, et al. B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events\u2014the Heinz Nixdorf Recall Study. Clin Res Cardiol. 2014;103(2):125\u201332.","journal-title":"Clin Res Cardiol"},{"key":"1271_CR11","first-page":"100553","volume":"29","author":"H Rudolf","year":"2020","unstructured":"Rudolf H, Mugge A, Trampisch HJ, Scharnagl H, Marz W, Kara K. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: the getABI-study. Int J Cardiol Heart Vasc. 2020;29:100553.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"19","key":"1271_CR12","doi-asserted-by":"publisher","first-page":"e017462","DOI":"10.1161\/JAHA.120.017462","volume":"9","author":"MVB Malachias","year":"2020","unstructured":"Malachias MVB, Jhund PS, Claggett BL, Wijkman MO, Bentley-Lewis R, Chaturvedi N, et al. NT-proBNP by itself predicts death and cardiovascular events in high-risk patients with type 2 diabetes mellitus. J Am Heart Assoc. 2020;9(19):e017462.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"1271_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.amjcard.2020.01.025","volume":"125","author":"K Nguyen","year":"2020","unstructured":"Nguyen K, Fan W, Bertoni A, Budoff MJ, Defilippi C, Lombardo D, et al. N-terminal Pro B-type natriuretic peptide and high-sensitivity cardiac troponin as markers for heart failure and cardiovascular disease risks according to glucose status (from the multi-ethnic study of atherosclerosis [MESA]). Am J Cardiol. 2020;125(8):1194\u2013201.","journal-title":"Am J Cardiol"},{"issue":"6","key":"1271_CR14","doi-asserted-by":"publisher","first-page":"e004743","DOI":"10.1161\/JAHA.116.004743","volume":"6","author":"E Wolsk","year":"2017","unstructured":"Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, et al. Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. J Am Heart Assoc. 2017;6(6):e004743.","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"1271_CR15","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.2337\/dc18-0109","volume":"41","author":"P Jarolim","year":"2018","unstructured":"Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA. Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE trial. Diabetes Care. 2018;41(7):1510\u20135.","journal-title":"Diabetes Care"},{"issue":"7","key":"1271_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMoa042330","volume":"352","author":"C Kragelund","year":"2005","unstructured":"Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352(7):666\u201375.","journal-title":"N Engl J Med"},{"issue":"2","key":"1271_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.atherosclerosis.2013.03.017","volume":"228","author":"N Ahluwalia","year":"2013","unstructured":"Ahluwalia N, Blacher J, Szabo de Edelenyi F, Faure P, Julia C, Hercberg S, et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis. 2013;228(2):478\u201384.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1271_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"6","key":"1271_CR19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/HYPERTENSIONAHA.118.11063","volume":"71","author":"HH Liu","year":"2018","unstructured":"Liu HH, Cao YX, Li S, Guo YL, Zhu CG, Wu NQ, et al. Impacts of prediabetes mellitus alone or plus hypertension on the coronary severity and cardiovascular outcomes. Hypertension. 2018;71(6):1039\u201346.","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"1271_CR20","first-page":"62-9","volume":"34","author":"A American Diabetes","year":"2011","unstructured":"American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(Suppl 1):62-9.","journal-title":"Diabetes Care"},{"key":"1271_CR21","doi-asserted-by":"publisher","first-page":"i5953","DOI":"10.1136\/bmj.i5953","volume":"355","author":"Y Huang","year":"2016","unstructured":"Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.","journal-title":"BMJ"},{"issue":"13","key":"1271_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jacc.2009.10.060","volume":"55","author":"ES Ford","year":"2010","unstructured":"Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55(13):1310\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"9833","key":"1271_CR23","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","volume":"379","author":"AG Tabak","year":"2012","unstructured":"Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279\u201390.","journal-title":"Lancet"},{"issue":"9626","key":"1271_CR24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(08)60766-7","volume":"371","author":"G Li","year":"2008","unstructured":"Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783\u20139.","journal-title":"Lancet"},{"issue":"21","key":"1271_CR25","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.ehj.2004.07.027","volume":"25","author":"M Bartnik","year":"2004","unstructured":"Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25(21):1880\u201390.","journal-title":"Eur Heart J"},{"issue":"1","key":"1271_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-019-0955-5","volume":"18","author":"M Takahara","year":"2019","unstructured":"Takahara M, Iida O, Kohsaka S, Soga Y, Fujihara M, Shinke T, et al. Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases. Cardiovasc Diabetol. 2019;18(1):155.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1271_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"1271_CR28","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.2147\/DMSO.S260990","volume":"13","author":"CL Chen","year":"2020","unstructured":"Chen CL, Liu L, Huang JY, Yu YL, Lo K, Huang YQ, et al. Systolic blood pressure, cardiovascular mortality, and all-cause mortality in normoglycemia, prediabetes, and diabetes. Diabetes Metab Syndr Obes. 2020;13:2375\u201388.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1271_CR29","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.2337\/dc19-0274","volume":"42","author":"JL Jin","year":"2019","unstructured":"Jin JL, Cao YX, Zhang HW, Sun D, Hua Q, Li YF, et al. Lipoprotein(a) and cardiovascular outcomes in coronary artery disease patients with prediabetes and diabetes. Diabetes Care. 2019;42:1312\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"1271_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12933-020-01012-9","volume":"19","author":"SL Liu","year":"2020","unstructured":"Liu SL, Wu NQ, Shi HW, Dong Q, Dong QT, Gao Y, et al. Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol. 2020;19(1):36.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"1271_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-019-0936-8","volume":"18","author":"JL Jin","year":"2019","unstructured":"Jin JL, Cao YX, Liu HH, Zhang HW, Guo YL, Wu NQ, et al. Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status. Cardiovasc Diabetol. 2019;18(1):134.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1271_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.dsx.2018.04.001","volume":"12","author":"R Garcia-Carretero","year":"2018","unstructured":"Garcia-Carretero R, Vigil-Medina L, Mora-Jimenez I, Soguero-Ruiz C, Goya-Esteban R, Ramos-Lopez J, et al. Cardiovascular risk assessment in prediabetic patients in a hypertensive population: the role of cystatin C. Diabetes Metab Syndr. 2018;12(5):625\u20139.","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"1271_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/1479164117738156","volume":"15","author":"YK Chung","year":"2018","unstructured":"Chung YK, Lee YJ, Kim KW, Cho RK, Chung SM, Moon JS, et al. Serum cystatin C is associated with subclinical atherosclerosis in patients with type 2 diabetes: a retrospective study. Diabetes Vasc Dis Res. 2018;15(1):24\u201330.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"7","key":"1271_CR34","doi-asserted-by":"publisher","first-page":"e001646","DOI":"10.1161\/JAHA.114.001646","volume":"4","author":"AL Beatty","year":"2015","unstructured":"Beatty AL, Ku IA, Bibbins-Domingo K, Christenson RH, DeFilippi CR, Ganz P, et al. Traditional risk factors versus biomarkers for prediction of secondary events in patients with stable coronary heart disease: from the heart and soul study. J Am Heart Assoc. 2015;4(7):e001646.","journal-title":"J Am Heart Assoc."},{"issue":"20","key":"1271_CR35","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1161\/01.CIR.0000147611.92021.2B","volume":"110","author":"C Heeschen","year":"2004","unstructured":"Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. Platelet receptor inhibition in ischemic syndrome management I. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110(20):3206\u201312.","journal-title":"Circulation"},{"issue":"23","key":"1271_CR36","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1161\/01.CIR.0000041661.63285.AE","volume":"106","author":"T Omland","year":"2002","unstructured":"Omland T, Persson A, Ng L, O\u2019Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106(23):2913\u20138.","journal-title":"Circulation"},{"issue":"6","key":"1271_CR37","doi-asserted-by":"publisher","first-page":"e001089","DOI":"10.1161\/JAHA.114.001089","volume":"3","author":"DA Schellings","year":"2014","unstructured":"Schellings DA, Adiyaman A, Giannitsis E, Hamm C, Suryapranata H, Ten Berg JM, et al. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score. J Am Heart Assoc. 2014;3(6):e001089.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"1271_CR38","first-page":"859","volume":"31","author":"XY Zhao","year":"2018","unstructured":"Zhao XY, Li JX, Tang XF, Xu JJ, Song Y, Jiang L, et al. Prognostic Value of NT-proBNP in stable coronary artery disease in Chinese patients after percutaneous coronary intervention in the drug-eluting stent era. Biomed Environ Sci. 2018;31(12):859\u201366.","journal-title":"Biomed Environ Sci"},{"key":"1271_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ahj.2020.12.017","volume":"233","author":"E Fabris","year":"2021","unstructured":"Fabris E, Ten Berg JM, Hermanides RS, Ottervanger JP, Dambrink JHE, Gosselink AM, et al. NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: insight from the on-TIME II trial. Am Heart J. 2021;233:78\u201385.","journal-title":"Am Heart J"},{"issue":"7","key":"1271_CR40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jacc.2017.06.030","volume":"70","author":"D Lindholm","year":"2017","unstructured":"Lindholm D, Lindback J, Armstrong PW, Budaj A, Cannon CP, Granger CB, et al. Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease. J Am Coll Cardiol. 2017;70(7):813\u201326.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1271_CR41","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1177\/2047487317717065","volume":"24","author":"M Pareek","year":"2017","unstructured":"Pareek M, Bhatt DL, Vaduganathan M, Biering-Sorensen T, Qamar A, Diederichsen AC, et al. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. Eur J Prev Cardiol. 2017;24(15):1648\u201359.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"1271_CR42","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1161\/01.CIR.92.6.1558","volume":"92","author":"N Hama","year":"1995","unstructured":"Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995;92(6):1558\u201364.","journal-title":"Circulation"},{"issue":"9","key":"1271_CR43","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1096\/fj.02-0796fje","volume":"17","author":"JP Goetze","year":"2003","unstructured":"Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17(9):1105\u20137.","journal-title":"FASEB J"},{"issue":"12","key":"1271_CR44","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2362.2011.02539.x","volume":"41","author":"S Neuhold","year":"2011","unstructured":"Neuhold S, Resl M, Huelsmann M, Strunk G, Adlbrecht C, Rath C, et al. Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. Eur J Clin Invest. 2011;41(12):1292\u20138.","journal-title":"Eur J Clin Invest"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01271-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T10:37:32Z","timestamp":1622630252000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01271-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the hospital\u2019s ethical review board (FuWai Hospital & National Center for Cardiovascular Diseases, Beijing, China). Each participant provided written, informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}